Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results

Provided By PR Newswire

Last update: Aug 10, 2023

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023

Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024